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Concurrent regulation of LKB1 and CaMKK2
in the activation of AMPK in castrate-
resistant prostate cancer by a well-defined
polyherbal mixture with anticancer
properties
Amber F. MacDonald1, Ahmed Bettaieb1, Dallas R. Donohoe1, Dina S. Alani1, Anna Han1,5, Yi Zhao1,4
and Jay Whelan1,2,3*
Abstract
Background: Zyflamend, a blend of herbal extracts, effectively inhibits tumor growth using preclinical models of
castrate-resistant prostate cancer mediated in part by 5′-adenosine monophosphate-activated protein kinase (AMPK)
, a master energy sensor of the cell. Clinically, treatment with Zyflamend and/or metformin (activators of AMPK) had
benefits in castrate-resistant prostate cancer patients who no longer responded to treatment. Two predominant
upstream kinases are known to activate AMPK: liver kinase B1 (LKB1), a tumor suppressor, and calcium-calmodulin
kinase kinase-2 (CaMKK2), a tumor promotor over-expressed in many cancers. The objective was to interrogate how
Zyflamend activates AMPK by determining the roles of LKB1 and CaMKK2.
Methods: AMPK activation was determined in CWR22Rv1 cells treated with a variety of inhibitors of LKB1 and
CaMKK2 in the presence and absence of Zyflamend, and in LKB1-null HeLa cells that constitutively express CaMKK2,
following transfection with wild type LKB1 or catalytically-dead mutants. Upstream regulation by Zyflamend of LKB1
and CaMKK2 was investigated targeting protein kinase C-zeta (PKCζ) and death-associated protein kinase (DAPK),
respectively.
Results: Zyflamend’s activation of AMPK appears to be LKB1 dependent, while simultaneously inhibiting
CaMKK2 activity. Zyflamend failed to rescue the activation of AMPK in the presence of pharmacological and
molecular inhibitors of LKB1, an effect not observed in the presence of inhibitors of CaMKK2. Using LKB1-null
and catalytically-dead LKB1-transfected HeLa cells that constitutively express CaMKK2, ionomycin (activator of
CaMKK2) increased phosphorylation of AMPK, but Zyflamend only had an effect in cells transfected with wild
type LKB1. Zyflamend appears to inhibit CaMKK2 by DAPK-mediated phosphorylation of CaMKK2 at Ser511, an
effect prevented by a DAPK inhibitor. Alternatively, Zyflamend mediates LKB1 activation via increased phosphorylation
of PKCζ, where it induced translocation of PKCζ and LKB1 to their respective active compartments in HeLa cells
following treatment. Altering the catalytic activity of LKB1 did not alter this translocation.
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Discussion: Zyflamend’s activation of AMPK is mediated by LKB1, possibly via PKCζ, but independent of CaMKK2 by a
mechanism that appears to involve DAPK.
Conclusions: Therefore, this is the first evidence that natural products simultaneously and antithetically regulate
upstream kinases, known to be involved in cancer, via the activation of AMPK.
Keywords: Zyflamend, AMPK, LKB1, CaMKK2, CWR22Rv1, HeLa, DAPK, PKC-zeta, Prostate cancer, Castrate-resistant
Background
Prostate cancer is the second leading cause of death for
men in the United States [1]. While early stages of the dis-
ease are treatable, with 5-year survival rates near 100%,
prognosis for advanced forms are less promising [2].
Initially, prostate cancer cells rely on androgens for
growth, and chemically-mediated deprivation (hormone
deprivation therapy) is a common therapy that results in
cancer regression [3]. Relapse in the absence of androgens
(castrate-resistant prostate cancer) is inevitable for most
individuals and is associated with increased expression
and activation of the androgen receptor, a major deter-
minant in survival [4, 5]. Due to the poor prognosis of
castrate-resistant prostate cancer, concomitant use of na-
tural products to enhance effectiveness is being explored
clinically and experimentally [3, 6–10].
Zyflamend (New Chapter, Inc. Brattleboro, VT) is a
poly-herbal supplement derived from the extracts of ten
different herbs: rosemary, turmeric, holy basil, ginger, green
tea, hu zhang, barberry, oregano, Chinese goldthread, and
baikal skullcap. Most research using Zyflamend has focused
its effects on a variety of cancer models, including oral [11],
mammary [12], bone [13], pancreas [14, 15], skin [11, 16],
colorectal [15], with an emphasis on prostate [6–9, 17–21],
and its beneficial effects appear to be related to the synergy
of action of its components [22]. The effects of Zyflamend
and its mechanisms on prostate cancer has been reviewed
elsewhere and can be summarized in Fig. 1 [3]. Zyflamend
inhibits signaling pathways of inflammation, affects cell
survival by enhancing apoptotic and tumor suppressor
genes, epigenetically modifies histones, down regulates the
androgen receptor and influences the energetics of the cell.
The latter pathways are critically important in cancer as
rapidly dividing cells rely on the increased synthesis of
macromolecules (lipids, proteins, nucleotides, etc) (as
reviewed in [23].
5′-adenosine monophosphate-activated protein kinase
(AMPK) is a key regulator of energy in the cell and
responds to deficits in adenosine triphosphate (ATP).
The protein contains a catalytic subunit (α-subunit),
and two regulatory subunits, β and γ-subunits. Under
conditions of energy stress the following occurs, (i)
increased levels of AMP or ADP bind to the
γ-subunit causing allosteric activation of the protein
(ATP is a competitive inhibitor), (ii) increased affinity
for upstream kinases that target phosphorylation at
Thr172 of the α-subunit (increasing catalytic activity
> 100 fold), and (iii) reduced affinity for phosphatases
that are involved in dephosphorylation at Thr172
[24]. When activated, AMPK is instrumental in inhi-
biting anabolic pathways that consume ATP, such as
lipogenesis and protein synthesis, and enhances
Fig. 1 Summary of the effects of Zyflamend on prostate cancer (with permission from reference [3])
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catabolic pathways that generate ATP, such as fatty
acid oxidation [23].
Clinically, treatment with Zyflamend and/or metformin
(activator of AMPK) had benefits in castrate-resistant
prostate cancer patients who no longer responded to a
variety of treatments (e.g., hormone ablation, immune-,
chemo-, and radiation therapy). Recently, it was deter-
mined that tumor suppressor properties of Zyflamend are
associated with the activation of AMPK and its
downstream signaling, where siRNA knockdown, pharma-
cological inhibition and over expression of AMPK
confirmed Zyflamend’s involvement [10]. This involves
inhibiting the mammalian target of rapamycin complex-1
(mTORC1) and protein synthesis, lipogenesis by targeting
the expression of (i) fatty acid synthase, (ii) the sterol regu-
latory element-binding transcription factor-1c, and (iii)
inhibiting the activity of acetyl CoA carboxylase (ACC).
What is not known is how Zyflamend upregulates AMPK.
Four kinases have been identified that activate AMPK at
Thr172, liver kinases B1 (LKB1), calcium-calmodulin
kinase kinase-2 (CaMKK2), transforming growth factor-β
activated protein kinase-1 (TAK1) and mixed lineage
kinase 3 (MLK3) [25–28]. LKB1 and CaMKK2 are import-
ant in a number of cancers, including castrate-resistant
prostate cancer (as reviewed in [29]), while the involve-
ment of TAK1 and MLK3 has yet to be determined. LKB1
responds to increases in AMP and ADP, while increases in
intracellular calcium is needed for activation of CaMKK2
without requiring elevation in AMP or ADP.
Interestingly, while both LKB1 and CaMKK2 are in-
volved in activating AMPK, their effects on cancer appear
to be quite different. LKB1 has anticancer properties
because its mutation/deletion is associated with a variety
of cancers [30]. CaMKK2, on the other hand, is overex-
pressed in a number of cancers, including
castrate-resistant prostate cancer [31, 32]. Therefore, the
overall objective of this paper was to interrogate how
Zyflamend activates AMPK in a model of
castrate-resistant prostate cancer and the roles LKB1 and
CaMKK2 play in that activation.
The major findings of this research revealed that al-
though LKB1 and CaMMK2 are upstream kinases that
can activate AMPK, Zyflamend inhibits CaMMK2, a
protein overexpressed in many cancers, while simultan-
eously upregulates LKB1, a reported tumor suppressor.
This is the first report linking the simultaneous
antagonistic regulation of these two proteins. Upstream
regulation of CaMKK2 appears to be mediated by the
antitumorigenic death associated protein kinase (DAPK)
[33–36], not epigenetically, but via phosphorylation at
Ser511 [37]. This is only the second paper to link DAPK
activity with the negative regulation of CaMKK2 via
phosphorylation at Ser511, and the only one involving
cancer cells.
Methods
Zyflamend (New Chapter, Inc. Brattleboro, VT), pur-
chased from Earth Fare Supermarket (Knoxville, TN), is
composed of extracts from the following herbs (w/w):
rosemary (Rosmarinus officinalis 19.2%), turmeric (Cur-
cuma longa 14.1%), holy basil (Ocimum sanctum 12.8%),
ginger (Zingiber officinale 12.8%), green tea (Camellia
sinensis 12.8%), hu zhang (Polygonum cuspidatum 10.2%),
barberry (Berberis vulgaris 5.1%), oregano (Origanum vul-
gare 5.1%), Chinese goldthread (Coptis chinensis 5.1%),
and baikal skullcap (Scutellaria baicalensis 2.5%). Detailed
description and characterization of the preparation of
Zyflamend and quality assurance of the mixture has been
described previously in detail [7]. This description in-
cludes rigorously generated verifiable quality control of its
constituents via multiple independent laboratories whose
biological effects have been duplicated using different lots,
at different times, under different experimental condi-
tions, in different laboratories across the United States.
Dulbecco’s Modified Eagle Medium (DMEM), G418,
penicillin/streptomycin, puromycin, fetal bovine serum
(FBS) and trypsin were purchased from Invitrogen
(Carlsbad, CA). Cloning vectors were purchased from
Addgene (Cambridge, MA). Antibodies for PKC-zeta
(PKCζ), LKB1, phospho-LKB1, green fluorescent protein
(GFP), Histone B, Flag, and Tubulin were from Santa
Cruz Biotechnology (Santa Cruz, CA). AMPK and
phospho-AMPK were from Cell Signaling Technology
(Beverly, MA). The following chemical reagents were
purchased: 5-aminoimidazole-4-carboxamide ribonucle-
otide (AICAR) (AdipoGen Life Sciences, San Diego,
CA); 1,2-bis(o-aminophenoxy)ethane-N,N,N′,N′-tetraa-
cetic acid acetoxymethyl ester (BAPTA-AM) and
ethylene glycol-bis(β-aminoethyl ether)-N,N,N′,N′-tetra-
acetic acid (EGTA) (Thermo Scientific, Rockville, IL);
STO-609, radicicol, and PKCζ Pseudo-substrate Inhibi-
tor (Santa Cruz Biotechnology, Dallas, TX); ionomycin
(Sigma-Aldrich, St. Louis, MO); and Death Associated
Protein Kinase Inhibitor (DAPKi) (Merck Millipore, Bil-
lerica, MA).
Cell culture
CWR22Rv1 cells (American Type Culture Collection,
Rockville, MD), a human-derived castrate-resistant pros-
tate cancer cell line, were cultured in RPMI 1640 media,
supplemented with 10% FBS. To mimic an
androgen-depleted state, the cells were incubated over-
night with 0.5% FBS. HeLa cells (ATCC, Rockville, MD), a
human-derived cervical cancer cell line that do not
express LKB1, and HCT116 cells (ATCC, Rockville, MD),
a human derived colorectal cancer cell line, were cultured
in DMEM media supplemented with 10% FBS and
25 mM glucose. All cells were incubated under an atmos-
phere of 5% CO2, at 37 °C. For activation of AMPK via
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LKB1-dependent or CaMKK2-dependent pathways, cells
were treated with AICAR (a cell permeable analog of
AMP) (1 mM, 1 h) or ionomycin (calcium ionophore)
(1 μM, 1 h), respectively. For experiments using inhibitors
of CaMKK2, cells were pre-treated with the selective
CaMKK2 inhibitor STO-609 (10 μM, 30 min) or the cal-
cium chelators BAPTA-AM (30 μM, 30 min) or EGTA
(2 mM, 30 min). For inhibition of LKB1 or DAPK, cells
were pre-treated with radicicol (5 μM, 24 h) or DAPKi
(20 μM, 24 h), respectively. For inhibition of PKCζ, cells
were pre-treated with the selective PKCζ pseudo-substrate
inhibitor (5 μM, 30 min). For all experiments involving
Zyflamend, cells were treated with Zyflamend at 200 μg/
mL for 30 min unless otherwise indicated.
Down regulation of LKB1 by small interfering RNA
CWR22Rv1 cells were seeded in RPMI medium contain-
ing 10% FBS and incubated overnight before media was
replaced with RNA transfection medium containing 0.5%
FBS. Cells were transfected with 20 nmol of siRNA target-
ing LKB1 (Thermo Scientific/Dharmacon #L-005035-00)
and a siRNA non-targeting control (Thermo Scientific/
Dharmacon #D-001810-10-05). Western blot analysis
confirmed the efficiency of knockdown to be 76% 48 h
after transfection, at which time cells were treated with a
vehicle or Zyflamend (200 μg/mL) for 30 min.
Overexpression of LKB1 in HeLa cells
Human WT or catalytically dead (KD) mutants of LKB1
were transfected into HeLa cells using Lipofectamine
3000 (Invitrogen, Carlsbad, CA) following manufac-
turer’s guidelines. Cells were cultured for additional 48 h
prior experiments. For total protein lysates, cells were
lysed in radio-immunoprecipitation assay buffer (RIPA:
10 M Tris-HCl, pH 7.4, 150 mM NaCl, 0.1% sodium do-
decyl sulfate [SDS], 1% Triton X-100, 1% sodium deoxy-
cholate, 5 mM EDTA, 1 mM NaF, 1 mM sodium
orthovanadate and protease inhibitors). Lysates were
clarified by centrifugation at 13,000 rpm for 10 min, and
protein concentrations were determined using a
bicinchoninic acid assay kit (Pierce Chemical). Pro-
teins (10 μg) were separated by SDS-polyacrylamide
gel electrophoresis (SDS-PAGE) (8–12%) [38], trans-
ferred to polyvinylidene difluoride (PVDF) membranes
and immunodetected using the indicated antibodies.
Proteins were detected using enhanced chemilumines-
cence (Amersham Biosciences). Resulting immunore-
active bands were quantified using FluorChem Q
Imaging software (Alpha Innotech).
Subcellular fractionation
Following Zyflamend treatment, fractionation was
performed in HeLa cells as described previously with
modifications [39, 40]. Briefly, cells were washed
with cold buffer A (100 mM sucrose, 1 mM EGTA,
20 mM 3-(N-morpholino)propanesulfonic acid
(MOPS), pH 7.4) and resuspended in lysis buffer B
(100 mM sucrose, 1 mM EGTA, 20 mM MOPS, 0.1
dithiothreitol (DTT), 5% freshly added percoll, 0.01%
digitonin, 1 mM phenylmethylsulfonyl fluoride
(PMSF) and cocktail of protease inhibitors, pH 7,4).
Membranes were broken using a dounce
homogenizer (200 strokes/sample). Debris and un-
broken cells were removed by centrifugation (500 g
for 10 min) and supernatants were then centrifuged
(2500 g, 5 min) to separate nuclei (pellet). Superna-
tants were centrifuged again (15,000 g, 15 min) to
separate mitochondria. Nuclear fraction was resus-
pended in radioimmunoprecipitation assay (RIPA)
buffer containing proteases inhibitors. Cellular distri-
bution and translocation of the indicated proteins
were analyzed by SDS-PAGE and Western blot as
described above. Purity of nuclear and cytoplasmic
fractions was verified using antibodies against
histone B and tubulin (Santa Cruz Biotechnology,
Dallas, TX), respectively.
Fig. 2 The effects of Zyflamend on cellular ATP levels and
phosphorylation of AMPKα (at Thr172) in CWR22Rv1 cells. a ATP
levels of CWR22Rv1 cells treated in the presence or absence of
Zyflamend (200 μg/mL, 30 min). b The effects of Zyflamend (200
μg/mL, 30 min – 3 h) on phosphorylation of AMPKα in CWR22Rv1
cells. Data is presented as mean ± SEM, n = 4. Abbreviations:
Con, Control
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Western blotting
Cells were lysed in RIPA lysis buffer (Thermo Scientific,
Rockford, IL). Protein concentration was measured using
a Bradford protein assay (Thermo Scientific, Rockford,
IL). Equal amount of protein (30 μg) were separated by
8% SDS-PAGE and transferred to a PVDF membrane by
electroblotting. Membranes were blocked by 5% non-fat
dry milk (LabScientific, Highlands, NJ) or bovine serum
albumin (Santa Cruz Biotechnology, Dallas, TX) in 0.1%
Tris-buffered saline-Tween-20 (TBST) for 1 h at room
temperature and incubated in TBST containing primary
antibodies overnight at 4 °C. Membranes were incubated
with anti-rabbit or anti-mouse secondary antibody
conjugated with horseradish peroxidase (HRP) (Cell Sig-
naling Technology, Danver, MA) for 1 h at room
temperature. Protein expression was detected with Super
Signal West Pico Chemiluminescent Substrate (Thermo
Scientific, Rockford, IL) and membranes were exposed
and analyzed via Li-Cor Odyssey FC imaging system
(Li-Cor, Lincoln, NE). Antibodies against p-AMPKα
(Thr172), AMPKα, p-ACC (Ser79), ACC, p-LKB1
(Ser428), LKB1, p- PKCζ (Thr410), PKCζ, and
p-CaMKKβ (Ser511) were used to detect target protein
level at 1:1000. β-Actin or glyceraldehyde 3-phosphate
dehydrogenase (GAPDH) (Santa Cruz Biotechnology,
Dallas, TX) was used as the loading control.
ATP assay
Cellular ATP concentration was determined using a
fluorometric ATP assay kit (BioRad, Milpitas, CA) fol-
lowing the manufacturer’s instructions, and fluorescence
Fig. 3 The effects of CaMKK2 inhibition by STO-609, BAPTA-AM and EGTA on pAMPKα (at Thr172) and pACC (at Ser79), ± Zyflamend in
CWR22Rv1 cells. (A-D) Western blot of pAMPKα and pACC following treatment of STO-609 (10 μM, 30 min) ± Zyflamend (200 μg/mL, 30 min). (E,
F) Western blot of pAMPKα following treatment of BAPTA-AM (30 μM, 30 min) ± Zyflamend (200 μg/mL, 30 min). (G, H) Western blot of pAMPKα
following treatment of EGTA (2 mM, 30 min) ± Zyflamend (200 μg/mL, 30 min). Data are presented as mean ± SEM, n = 3. Bars with different
letters are statistically different at p < 0.05. Abbreviations: BAP, BAPTA-AM (1, 2-bis(o-aminophenoxy)ethane-N,N,N′,N′-tetraacetic acid acetoxymethyl
ester); CON, Control; EGTA, ethylene glycol-bis (β-aminoethyl ether)-N, N, N′,N′-tetraacetic acid; STO, STO-609; Zyf, Zyflamend
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was read at 525 nm on a Glowmax Multi Detection
System (Promega Corporation, Madison, WI).
Statistics
For Western blot, protein was analyzed from 3 independent
samples and presented as mean ± SEM. For ATP concen-
tration, results are presented as mean ± SEM. For multiple
comparisons, data was analyzed using IBM SPSS Statistics
24 and tested by one-way analysis of variance (ANOVA)
followed by a Tukey’s post-hoc test. Two-group compari-
sons were analyzed by two-tailed Student’s T-test. Results
were considered statistically significant at p < 0.05.
Results
Effect of Zyflamend on cell proliferation, ATP levels and
AMPK phosphorylation in CWR22Rv1 cells
Zyflamend (200 μg/mL) inhibited cell proliferation in
CWR22Rv1 cells in a concentration and time dependent
manner (Additional file 1: Figure S1, replicating previously
published results [6, 8]). Similar results were replicated in
a variety of immortalized prostate-derived cells lines [8]
and in the HCT116 colorectal cell line (Additional file 2:
Figure S2). Because Zyflamend has been shown to change
the energetics of CWR22Rv1 cells [3, 10], levels of ATP
were determined. In the presence of Zyflamend, ATP
levels were reduced by ~ 40% (Fig. 2a) and AMPK phos-
phorylation (Thr172) was significantly increased (Fig. 2b).
These results were replicated in the HCT116 colorectal
cell line to demonstrate that these effects are not specific
for prostate cancer cells (Additional file 2: Figure S2).
AMPK activation by CaMKK2 in the presence and absence
of Zyflamend in CWR22Rv1 cells
Zyflamend significantly increased the phosphorylation of
AMPK (Thr172) (Fig. 3A and B) and its downstream target
ACC (Ser79) (Fig. 3C and D), results unaffected by pretreat-
ment with the CaMKK2 inhibitor STO-609 (Fig. 3A-D, lane
4/bar 4). To confirm that the activation of AMPK by Zyfla-
mend is independent of CaMKK2, cells were pre-treated
with the calcium chelators BAPTA-AM and EGTA, as
CaMKK2 activation is dependent upon intracellular calcium.
Pretreatment with BAPTA-AM (Fig. 3E and F) and EGTA
(Fig. 3G and H) failed to prevent phosphorylation of AMPK
in the presence of Zyflamend. Zyflamend increased the
phosphorylation of CaMKK2 at Ser511 (Fig. 4A), a phos-
phorylation site that results in its inhibition and reported to
be mediated by DAPK [37]. Pretreatment with a DAPK
inhibitor attenuated Zyflamend’s ability to increase phos-
phorylation of CaMKK2 at Ser511 in a time-dependent
manner (Fig. 4A-C), suggesting phosphorylation of
CaMKK2 in the presence of Zyflamend is mediated by
DAPK. Pretreatment of cells with DAPKi failed to prevent
phosphorylation of AMPK in the presence of Zyflamend,
further confirming that the activation of AMPK by Zyfla-
mend is independent of CaMKK2 (Fig. 4D and E).
AMPK activation by LKB1 in the presence and absence of
Zyflamend in CWR22Rv1 cells
Zyflamend significantly increased the phosphorylation of
LKB1 (Ser428) (Fig. 5A), AMPK (Thr172) (Fig. 5C) and
ACC (Ser79) (Fig. 5E). In the presence of radicicol, a
Fig. 4 The effects of Zyflamend and an inhibitor of DAPK on the phosphorylation of CaMKK2 (at Ser511), in CWR22Rv1 cells. A Western blot of
pCaMKK2 ± Zyflamend (200 μg/mL, 30 min) and following treatment of DAPKi (20 μM, 1 h – 24 h) followed by the treatment of Zyflamend (200
μg/mL, 30 min). B, C Western blot and graph comparison of pCaMKK2 following treatment of DAPKi (20 μM, 24 h) ± Zyflamend (200 μg/mL,
30 min). (D, E) Western blot and graph comparison of pAMPK following treatment of Zyflamend (200 μg/mL, 30 min) and DAPKi (20 μM, 24 h) ±
Zyflamend (200 μg/mL, 30 min). Data are presented as mean ± SEM, n = 3. Bars with different letters are statistically different at p < 0.05.
Abbreviations: CON, Control; DAPKi, DAPK inhibitor; Zyf, Zyflamend
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non-specific inhibitor of LKB1 that results in reduction
of total LKB1 protein levels (Fig. 5C, row 3, column 3),
phosphorylation of AMPK failed to be fully restored
upon Zyflamend treatment (Fig. 5B and C). Likewise,
knockdown of LKB1 by siRNA (Fig. 5d-f ) inhibited
Zyflamend-induced phosphorylation of AMPK (Fig. 5D
and E) and its downstream target ACC (Fig. 5E and F).
Zyflamend-induced AMPK phosphorylation is LKB1
dependent
To confirm that Zyflamend-induced phosphorylation of
AMPK is LKB1 dependent and CaMKK2 independent, we
treated LKB1-null HeLa cells, that constitutively express
CaMKK2, with AICAR (an activator of AMPK that is com-
monly used as a positive control), ionomycin (activator of
CaMKK2) and Zyflamend (Fig. 6a). The same experiment
was conducted on HeLa cells that were stably transfected
with the wild-type (WT) or the catalytically dead (KD) mu-
tants of the human LKB1. Two different constructs of the
KD mutants were used, Flag-tagged or green fluorescent
protein (KD-LKB1 Flag or KD-LKB1 GFP, respectively)
(Fig. 6b). In both mutants, lysine 78 was mutated to isoleu-
cine, abolishing auto-phosphorylation and activation of
LKB1 [41, 42]. Ionomycin (Fig. 6b, column 3), but not
AICAR (column 2) or Zyflamend (column 4), induced
phosphorylation of AMPK in LKB1-null HeLa cells (con-
trol) (Fig. 6b, columns 1–5). Following transfection with
WT-LKB1 (Fig. 6b, columns 6–8), Zyflamend induced
phosphorylation of LKB1 and AMPK (column 7), an effect
more pronounced with co-treatment of AICAR (column 8).
However, no phosphorylation of LKB1 and AMPK was ob-
served in the KD mutants following treatment with Zyfla-
mend and Zyflamend+AICAR (Fig. 6b, columns 9–14).
Zyflamend-mediated LKB1 phosphorylation is linked to
PKCzeta
In an effort to determine how Zyflamend may be mediat-
ing the phosphorylation of LKB1, PKCζ was investigated
Fig. 5 The effects of Zyflamend on phosphorylation of LKB1 (at Ser428) and AMPKα (at Thr172) following inhibition with radicicol and
knockdown of LKB1 in CWR22Rv1 cells. A Western blot of pLKB1 ± Zyflamend (200 μg/mL, 30 min – 3 h). B, C Western blot of pAMPKα following
treatment with radicicol (5 μM, 24 h) ± Zyflamend (200 μg/mL, 30 min). D-F Western blot of pAMPKα and pACC (at Ser79) following knockdown
of LKB1 ± Zyflamend (200 μg/mL, 30 min). Data are presented as mean ± SEM, n = 3. Bars with different letters are statistically different at p < 0.05.
Abbreviations: CON, Control; Rad, Radicicol; Zyf, Zyflamend
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as a possible upstream target (Fig. 7). Phosphorylation of
PKCζ and LKB1 increased when CWR22Rv1 cells were
treated with Zyflamend (Fig. 7A). However, in the pres-
ence of a highly selective PKCζ pseudo-substrate inhibitor,
phosphorylation of LKB1 could not be restored to control
levels following Zyflamend treatment (Fig. 7B and C).
Using our informative HeLa cell constructs, null for LKB1
and transfected with WT-LKB1 or KD-LKB1, we further
investigated the relationship between PKCζ and LKB1
(Fig. 7D). In HeLa cells devoid of LKB1 (control cells),
PKCζ is located in the cytosol (Fig. 7D, row 1, col-
umn 3), but appears to translocate to the nucleus
upon treatment with Zyflamend (Fig. 7D, row 1, col-
umn 2). In cells transfected with WT-LKB1, PKCζ is lo-
cated in the cytosol (Fig. 7D, row 1, column 7) and LKB1
is located in the nucleus (Fig. 7D, row 2, column 5). Fol-
lowing Zyflamend treatment, their locations switch, where
PKCζ translocates to the nucleus (Fig. 7D, row 1, column
6) and LKB1 is found in the cytosol (Fig. 7D, row 2, col-
umn 8). This translocation following Zyflamend treatment
appears to be independent of a catalytically active protein,
as the same results were observed with the KD-LKB1
mutant (Fig. 7D, columns 9–12).
Discussion
Zyflamend is a unique blend of ten herbal extracts with
tumor suppressor properties whose biochemical and physio-
logical effects have been replicated in different laboratories,
at different times, using different lots, with similar doses/
concentrations [6–8, 10, 11, 13–17, 19, 21, 43]. The quality
control of this preparation has been summarized elsewhere
[7] and is most likely responsible for the reproducibility of
results. Importantly, the effects of Zyflamend have been re-
ported in a variety of cell lines, not just prostate cancer cells
(CWR22, CWR22R, CWR22Rv1, PC3, LNCaP, RWPE-1,
RAW 264.7, H1299, KBM-5, U266, MeW0, A365,
Fig. 6 Effects of Zyflamend on pAMPK (at Thr172) and pLKB1 (at Ser428) in HeLa cells null for LKB1, transfected with wild type (WT) LKB1 or with
two catalytically dead (KD) mutants of LKB1. a Western blot of pAMPK in HeLa cells ± AICAR, (1 mM, 1 h), ionomycin (1 μM, 1 h) or Zyflamend
(200 μg/mL, 30 min – 3 h). (b) Western blot of pAMPK in HeLa cells, WT-LKB1 HeLa cells, and KD-LKB1 HeLa cells ± AICAR (1 mM, 1 h), ionomycin
(1 μM, 1 h), and/or Zyflamend (200 μg/mL, 1 h). Representative immunoblots from 3 independent experiments are shown. Abbreviations: Con,
Control; DMSO, dimethyl sulfoxide; Ion, ionomycin; Zyf, Zyflamend
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MSK-Leuk1, HaCaT, HCT116, THP-1, HEK293) [6–8, 10–
19, 21, 43]. While there is clinical evidence for the beneficial
effects of Zyflamend on prostate cancer [9, 18, 20, 44], it is
not possible to tease out the contributions and/or interac-
tions of each constituent due to the high number of possible
combinations (as many as 1024). However, recent studies
have demonstrated that combining components from this
blend enhances their cellular and molecular effects by orders
of magnitude as compared to isolated components, indicat-
ing highly synergistic interactions when combined [22]. The
ability of this mixture to function at human equivalent doses
and in clinical trials is most likely due to this synergy. This
combination has been shown to be clinically effective in
prostate cancer patients by reducing levels of prostate
specific antigen (PSA), a biomarker used to monitor prostate
cancer progression. Case studies from M.D. Anderson
Cancer Center report dramatic reductions in PSA levels
following treatment with Zyflamend and/or metformin (an
activator of AMPK) in patients whose prostate cancer no
longer responds to a variety of standard therapies [9], an ef-
fect also observed in our recent clinical trial with prostate
cancer patients undergoing radical prostatectomy [44].
Castrate-resistant prostate cancer is the focus of this re-
search and the research in our laboratory. To study mech-
anisms of action, we use human prostate cancer cells
derived from the CWR22 lineage [6–8, 10, 45, 46]. Similar
to the progression of human prostate cancer, these cells
are originally androgen dependent and can transform to a
Fig. 7 The effects of Zyflamend on phosphorylation of PKCζ (at Thr410) and cellular location of PKCζ and LKB1 in HeLa cells null for LKB1,
transfected with wild type (WT) LKB1 or with a catalytically dead (KD) mutant of LKB1. A Western blot of phosphorylation of PKCζ ± Zyflamend
(200 μg/mL, 30 min – 3 h). B, C Western blot of pLKB1 (at Ser428) following treatment with Zyflamend, PKCζ inhibitor (5 μM, 30 min) or
pretreatment with the PKCζ inhibitor plus Zyflamend (200 μg/mL, 30 min). D Western blot for PKCζ and LKB1 following subcellular fractionation
(cytosol and nucleus) in HeLa cells null for LKB1, transfected with WT LKB1 or with a KD mutant of LKB1 treated with or without Zyflamend (200
μg/mL, 1 h). Representative immunoblots from 3 independent experiments are shown. Abbreviations: CON, Control; Pi, PKCζ inhibitor;
Zyf, Zyflamend
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castrate-resistant line in vivo (i.e., CRW22R) following
hormone ablation [46–48]. Unlike some other prostate
cancer cell lines (i.e., PC3 cells), the CWR22Rv1 cells ex-
press a constitutively active androgen receptor and PSA,
characteristics shared by castrate-resistant prostate cancer
in humans.
The effectiveness of Zyflamend on prostate cancer rests,
in part, with its ability to upregulate AMPK, an effect ob-
served in other cell types and tissues (i.e., HCT116, PC3,
adipose) suggesting a general effect [10, 44]. However, the
mechanism as to how Zyflamend upregulates AMPK is un-
known, although many of its constituents have been shown
to independently activate AMPK by modifying mitochon-
drial ATP production (as reviewed in [49]). This is the first
paper to delineate the coordination of potential upstream
pathways involved in the activation of AMPK, viz., LKB1
and CaMKK2, and to do so using natural products.
The role of AMPK in prostate cancer is controversial
in the sense that upstream kinases responsible for its ac-
tivation appear to have contradictory effects on cancer
[29]. CaMKK2 is a known tumor promotor whose ex-
pression is linked to the upregulation of the androgen
receptor, a key step in castrate-resistant prostate cancer
[4, 31]. Interestingly, Zyflamend down regulates the an-
drogen receptor and its nuclear localization [6]. DAPK
is a differentially methylated gene where most of its
effects on cancer have focused on its epigenetic
regulation [33–36]. Uniquely, a catalytic downstream
target of DAPK is CaMKK2 where it phosphorylates
CaMKK2 at Ser511 [37], a site adjacent to the Ca+
2-calmodulin regulatory domain, preventing autophos-
phorylation and inhibiting catalytic activity [37].
In contrast, LKB1 exhibits tumor suppressor proper-
ties, where loss of LKB1 is involved in a variety of
cancers [24, 30]. LKB1-mediated activation of AMPK is
dependent upon increases in the AMP(ADP):ATP ratios.
Zyflamend significantly decreases ATP in the cells. LKB1
contains a nuclear localization domain and is typically
(but not always exclusively) found in the nucleus. Fol-
lowing activation, LKB1 co-localizes with STE20-related
adaptor (known as STRAD) protein and scaffolding
mouse 25 (known as MO25) protein and translocates to
the cytosol where it exerts its kinase activity on a num-
ber of downstream targets, including AMPK [50]. Nu-
clear export, in part, appears to involve phosphorylation
at Ser428 by PKCζ [51].
A key finding from this research is that Zyflamend anti-
thetically regulates two parallel pathways important in the
phosphorylation of AMPK that is potentially important in
castrate-resistant prostate cancer. These effects are summa-
rized in Fig. 8. Zyflamend-mediated activation of AMPK
appears to be LKB1 dependent, while coordinately and
negatively regulating CaMKK2 activity. This was ob-
served using LKB1-null and KD-LKB1 transfected
HeLa cells that constitutively express CaMKK2. The
addition of ionomycin (activator of CaMKK2) robustly
increased phosphorylation of AMPK, but Zyflamend
(with and without AICAR, an AMP analog) had no
effect. Our results suggest that Zyflamend inhibits
CaMKK2 following DAPK-mediated phosphorylation
at Ser511, as this effect is prevented by the presence
of a DAPK inhibitor.
On the other hand, Zyflamend robustly increased the
phosphorylation of AMPK only in HeLa cells transfected
with WT LKB1. Using the various constructs of the
HeLa cells, we confirmed nuclear localization of LKB1,
with translocation to the cytosol following Zyflamend
treatment (Fig. 7). Zyflamend increased phosphorylation
Fig. 8 Summary of the effects of Zyflamend on AMPK regulation by signaling pathways of LKB1 and CaMKK2. Zyflamend has been shown to
inhibit castrate-resistant prostate cancer, in part, through the activation of AMPK. This activation is mediated by the increase in AMP:ATP ratio and
the activation of the tumor suppressor protein LKB1 following phosphorylation by PKCζ. Simultaneously, Zyflamend inhibits the tumor promotor
CaMKK2 via phosphorylation at Ser511 by DAPK
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of PKCζ, a known activator of LKB1, and inhibition of
PKCζ reduced LKB1 phosphorylation in the presence of
Zyflamend. Importantly, translocation of PKCζ from the
cytosol to the nucleus occurred concomitantly.
These results help explain why inhibitors of CaMKK2
(STO-609, BAPTA-AM, EGTA, DAPKi) failed to pre-
vent the activation of AMPK in the presence of Zyfla-
mend in CWR22Rv1 cells. This was due to the
simultaneous activation of LKB1, and this was confirmed
when activation of AMPK (in the presence of Zyfla-
mend) was not completely rescued following inhibition
(radicicol) and knockdown (siRNA) of LKB1.
Conclusions
In summary, Zyflamend has been shown to inhibit
castrate-resistant prostate cancer, in part, through the
activation of AMPK, results confirmed using chemical
and molecular interventions [10]. In conjunction with
reducing ATP levels, this activation is mediated by the
tumor suppressor protein LKB1, via activation of PKCζ.
Simultaneously, Zyflamend inhibits CaMKK2, a tumor
promotor that is over-expressed in many cancers, in-
cluding castrate-resistant prostate cancer. This inhibition
appears to be uniquely mediated by DAPK. More studies
are warranted to interrogate the relationship of Zyfla-
mend with DAPK signaling. In conclusion, this is the
first evidence that multiple upstream pathways involved
in the activation of AMPK, an important signaling mol-
ecule in cancer, can be simultaneously regulated using a
well-defined natural product.
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